you, call. morning. has Thank who joined good Tom, appreciate We everyone us on this and
focus that will organic the growth was divestitures quarter Before $X.X Consolidated which of today billion comments I versus the the discontinuations. on for revenue start, note prior organic and revenue, year. flat first my exchange, please on foreign excludes revenue impact with
in capacity focus First the Solta on as challenging and an already geopolitical input offset effects billion, low Pharma with we tight these was versus impacting US costs. lower environment and lockdowns on average a well was of continues QX were home in supply chain, supply X% tensions quarter the resulting revenues the our care an basis for pressure which organic This Omicron The primary increased Bausch in as created Navigating create as price, an and nursing resurgence single-digit have inflationary on a agility ripple challenges requires the driven COVID increase to last safeguard volume. China. by by products. down year. $X
me each more of on our details provide Let segments.
Please refer new International, can to that will a Slide Medical B&L. Products, Salix, for Bausch Slide starting Solta of our reporting Diversified or report You + results. under guide. quick note summary Lomb sales this a XX X our see for segments: we sales Please and quarter
partially growth, market surge Salix estimate certain million. slowed and were continued non-recurrence investments We The mid-teens of first we comparison year-on-year grew in million lower versus was $XXX year. prior XIFAXAN the $XX Omicron of high and year, wholesaler Page inventory revenue the of the to to digital digits in gains. US TRx exclusivity quarter first the the and decline of also to impacted fourth year-over-year accelerate due healthy growth XIFAXAN increased our was record the revenues that approximately X% loss sales the XX. in share on reduction in favorable related related the quarter. last TRULANCE marketing The this low-single to are following quarter products. rebalancing in volumes by to volumes. behind a Turning down sales the increasing The
the on market can XX see to gain key page You Salix continue that share. brands
Turning as and and driven excludes Amoun to was continued strength million page FX $XXX headwinds. organic growth and the the discontinuations, impact XX. International of in which revenues delivered as well of of by quarter primarily Canada X%, divestitures growth The EMEA. first
As of a products potential accounting reminder, with is with XX% sales our of of portfolio over loss a business business for risk than from highly diverse greater and a XXX product segment no no international single exclusivity. durable
Derm business. diversified to now Turning the products, includes which Ortho
reported net XX% combined million revenues of by XX% down realized $XXX revenue APLENZIN, quarter pricing. versus First year. and in increase driven last were a WELLBUTRIN
to Our and PEPCID, MYSOLINE. arising from unfavorable neuro down due demand year XX% ATIVAN comps the business COVID-related for was last
Our XX%, primarily due competition. new down was to generics business
dentistry were sales flat. down dermatology Our XX%, was while
Lastly, Solta these one-third to on components first business a estimate impacted year-over-year in of We by about factors XX $XX the Solta's was two the in page and growth million, percentage quarter. revenue XX, flat lockdowns Medical's the first of for accounts critical about China, due which points shortfall quarter. in COVID
We and issue. the resolving quarter continue factors are on expect the to focused microchip second these into
COVID expect well China as the We in to abate year as progresses. lockdown
maximizing for at to this of shareholder full The and now Our on impact temporary will business the rates, value. revenue revised guidance continue year well-positioned reflects to focus we is grow attractive growth.
provide brief me Bausch commentary let + Lomb. on Now
results. As reminder, the consolidated quarter first is B+L's a with fully
of organic to XX. with year the + up to guidance China line were momentum and heading due in in into Bausch revenues growth $XXX strong full million and Turning enabled related million lockdowns Page Lomb's softness X% for quarter. is The XXXX. the which X% organically, of us headwinds for in quarter first XXXX to the $XX overcome X% drove solid to performance COVID our currency
many see to for business now growth the continuing is as the of to includes includes which this the and reflects increase. in continue SiHy contact quarter to invest durability Care sales continue COVID-related R&D in $XXX for segment, dynamic consumables IOLs ramp-up through the and quarter, to for the approximately this segment, consumer our The by the new we Global are the adding which momentum Surgical to mega BioTrue. and Surgical lenses and and market to Adjusted the eye we Vision and commitment of the X% come. In to was in years segments. trends for launch the the of expense works saw led strong and growth Daily continues driving see growth. number backlog We expect was demand products. franchises, Care and procedures Vision growth to key business LUMIFY The products, EBITDA in lens In million support vitamins, the
Daily about continue business, are lenses the l the and another view In launched launch expect year. as March. the the year we XIPERE in and of with launch the later multifocal this recent to Ophtho this smart the Malaysia, the and countries a in in global we we portfolio. first Rx transformation the Europe late in SiHy step of We markets this XXXX, rollout QX of During XX XX different excited
the be XXXX, launch and catalysts Lucentis NOVOX products, in additional two we growth. expect view which will We biosimilar accelerate to to
grew in over by TRxs first Vyzulta the up and XX% Finally, international the were XX%, quarter. Optho organically
XX. share find performance our on market a You'll of Page summary
on the to focus I'm Page going XX. non-GAAP consolidated on P&L quarter. comments results the to Turning for my
was inflation We inflationary gross year, driven driven versus points and spending compared the Bausch on in and in crisis was spending continue launches in last currency higher EBITDA product been one-third driven expenses operating and R&D decreased have costs business. constant represented million, increase the the currency returned energy X% since a of in selling and of million which product input R&D. XXXX, EBITDA adjusted first by Adjusted to compared to expenses were last X.X% XX% pre-COVID freight, compared basis experience quarter, constant XX% on China. for market last to to other the the to decline in margin R&D to quarter XX% in basis sales Salix. XX $XXX higher last from First $XXX current by as business for down support and + Adjusted last year. a by year, year was Adjusted selling significant began to Russia-Ukraine year's and XX% and up an invest driven invest half lockdowns higher conditions. basis of this by by the quarter as late versus exacerbated expenses X.X% we pressures margin levels Lomb with
$XX from on a last discuss after the from hand. was me from for legal year -- loans legal impacted our of term senior using operations ended let and billion million, XX XX. secured after with GAAP cash Pages is settlements $XX.X timing million We Bosch adjusted cash which settlements, $XXX payments. cash flow on down debt repaying due balance to We excluding $XXX sheet these of net of primarily Pharma on million Now quarter after the of used operations by legacy basis,
to Page XX. Turning
close capital of The debt structure + a before few raising with transactions loans. Lomb you underwriting Let Bausch as costs. of billion in resulted since through the quarter expects IPO today, gross the the and to also Concurrent $X.X cash Lomb + moments to me take term new on million new issuance proceeds of IPO, $XXX its walk a to changes Bausch end. our related IPO result
quarter the from secured Pharma for to balance IPO raise, $XX.X at in the net as billion The our Bosch proceeds billion secured proceeds the you'll January the and cash at quarter the XXXX offering. that $XX $X.X debt plus $X since reduce the from end, will by BHC the proceeds today. new from and from a bond approximately billion debt offering end recall this bond of of QX XXXX, includes addition, In raised debt unconsolidated taking of end billion had
Finally, BHC of new with new entered is in loans closing $X.X also facility which into XXXX, a billion, today. term credit January
profile and today, on have billion. with in significant of by these closing see through and progress $X transactions XXXX our have we debt, the debt reducing made you of will page As obligations the expected maturity XX, we approximately our our debt extended
the our any XX% and XXXX. Bausch of rest required retaining the fixed Bausch leverage ratio Health is + bank its post under fixed to while of to unrestricted. do cash to until Bausch is be important a Health. until approximately under structure bonds, IPO, then our to transactions, the business. these currently remain debt It's Health the continue facility flexibility restricted ratio available subsidiary designates as Lomb's Lomb we Following will Lomb and debt in the We'll + not our achieved Bausch Bausch under to and + Bausch instruments flow Bausch that charge have maturities optimize coverage capital the note required invest Health not
proceeds able unrestrict a deleveraging result initially than of not the to yet As P&L. and are we the IPO lower less in contemplated,
XXth, is time will still a status on for standpoint, ability no being, business, for a its have not Bausch remains of the We longer our material a However, Pharma restricted that believe or its as a P&L restricted cash. capital From Pharma's combined B+L for although operate use business and the subsidiary debt. to plan. Solta allocation of unconsolidated is effect Bausch deleveraging priority any it of a guarantor as subsidiary May implement
organically We inorganically. business will and the also invest to grow
leverage approximately continuing business, cash potential rate improve by while conversion to we our to attractive turns R&D returns. invest the ability the up net ratio in Given to X.XX with to year, the deliver projects have high per flow the of
and our let year, Now slides can few me outlook to find which take the XX. XX a discuss moments you on for
organic total the to are for of our business X%. outlook for growth reaffirming Bosch We X% Health
X% organic on a basis And billion. X%; and the $X.XX to expect guidance X%; revenue B+L $X.X Our of range on to Bausch to in an Pharma X% basis, X% consolidated Solta to to X%. we grow is billion
of full $X.XXX an consolidated Bausch EBITDA to appropriate + Given On that and post-IPO an provide $XXX pressure a experienced now public. limited the to Lomb This basis, the have B+L Based segment. close anticipate billion closing we that higher B&L when Lomb COVID on representing of million with of billion in we after first as guidance IPO FX XXXX quarter the generate guidance rates, XXXX, dissynergies has we expected and is over the for law. is approximately gone to do impact IPO total to current today, compliance EBIT later incremental moving of expect impact and since The February we FX forward FX year impact $XX such which February $XX will Bausch EBITDA million, so $X.XXX adjusted provide in of approximately since + FX our $XXX million incremental million is our an the assumes guidance. -- adjusted for guidance. applicable XXXX. ongoing of on will
Our second assumes the inflationary and last the term. in the China headwinds near that through that guidance remain quarter lockdowns
slow in execute We this near year the growth capacity expect support the this term, environment. to care US recovery ways commercial dampen patient needs new the TRx strategy our to will in and in health
XX.X% inflation. to product mix gross of to We compared margin year based expect full and XX% due previously net
offset for and through look products these pressures keeping continue access. We affordable operating growing efficiency to ways market our while to
marketing rate expenses on previously year. to grow pullback $XXX million spending this We a expect full continue and year the last of after Furthermore, and run had to invest basis. R&D estimated and selling year the dissynergies significant in business in we
starting the for quarter. million results estimate begin these this Following $XXX into We dissynergies our we in second the of balance the IPO incorporate Bausch + of of Lomb, will costs to non-GAAP year.
forecast expense of loans are the debt. expect billion offset from new year, Please $X.X cost a billion that expense partially term this to full For interest note includes of B&L for that the basis, debt, today. we consolidated due the $X.XX interest closing on paydown savings the of expense interest by higher from
expect Assuming from to debt we no from $X.XX transactions, or markets billion generate further cash operations. capital flow
a up, you update reporting let will as I Bausch the take move towards Lomb. moment change our forward we Before + to financial spin-off wrap of me on how
Going interest + our until we distribution, B&L's majority will a distribution. we XX% its to and to as expect results consolidate Bausch Lomb a forward, discontinued the report stake operation. report reflect complete we After
Now let me back Tom turn remarks. to the concluding floor for Appio
